Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 07:05:54 ET More on Merck Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript) Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative Merck: Right On Time ...
2023-10-23 09:02:58 ET Summary Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown pro...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...
2023-10-20 11:12:54 ET More on Merck Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck study shows Keytruda can help lower death risk from cervical canc...
2023-10-19 23:52:31 ET More on Daiichi, Merck, etc. Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects AstraZeneca drops after Phase 3 data for lung cancer the...
2023-10-18 10:25:26 ET More on AstraZeneca, Daiichi, etc. AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript ...
2023-10-13 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...